Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Pazopanib HCl
Cat No.
CEI-0009
Description
Pazopanib (GW786034B; GlaxoSmithKline) is a novel multi-targeted, orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor 1, VEGF receptor 2, and VEGF receptor 3 with IC50 values of 10, 30, and 47 nM.
Alias
GW786034
CAS No.
635702-64-6
Molecular Weight
473.98
Purity
>99%
Storage
2 years at -20 centigrade
Synonyms
GW786034
Targets
VEGFR1, VEGFR2, VEGFR3
Molecular Formula
C21H23N7O2S.HCl
Chemical Name
5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride
Solubility
DSMO 70 mg/mL Water 17 mg/mL Ethanol
In vitro
Pazopanib (GW786034B; GlaxoSmithKline) is a novel multi-targeted, orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor 1, VEGF receptor 2, and VEGF receptor 3 with IC50 values of 10 nM, 30 nM, and 47 nM. Pazopanib (GW786034B; GlaxoSmithKline) also shows inhibition to platelet-derived growth factor receptor (including PDGFR-alpha and PDGFR-beta), and c-kit, FGF-R1, and c-fms with IC50 of 84, 74, 140, and 146 nM. Pazopanib can inhibit MM cell growth, survival, and migration. It can inhibit MM cell lines including dexamethasone-sensitive MM.1S, dexamethasone resistant MM.1R, doxorubicin (Dox)-sensitive RPMI, Dox-resistant RPMI (Dox40), IL-6-dependent INA-6, OPM2, and U266. Pazopanib suppresses VEGF-Induced Endothelial Cell Proliferation and Migration.
Download
Download Datasheet